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Abstract
We determined the diagnostic yield of the Xpert MTB/RIF assay for tuberculosis (TB) when
testing small volumes of urine from ambulatory HIV-infected patients prior to starting
antiretroviral therapy (ART) in South Africa. Compared to a gold standard of sputum culture, the
sensitivity of urine Xpert among those with CD4 cell counts of <50, 50-100 and >100 cells/μL
were 44.4%, 25.0% and 2.7% (P=0.001), respectively. Urine Xpert testing provides a means of
rapid TB diagnosis in patients with advanced immunodeficiency and poor prognosis. These data
are indicative of high rates of TB dissemination and renal involvement in this clinical population.
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INTRODUCTION
Tuberculosis (TB) is a leading cause of morbidity and mortality in HIV-infected patients
accessing antiretroviral treatment (ART) programmes or requiring medical admission to
hospitals in sub-Saharan Africa.1-5 However, diagnosis of TB in these patient groups is
often missed or delayed as a result of the non-specific clinical presentation, high rates of
sputum smear-negative, extrapulmonary and disseminated disease, and the limited utility of
pulmonary radiology.6,7 There is a great need for new diagnostic tools to increase the
sensitivity and speed of diagnosis in these patient groups, especially in view of their high
mortality and the risk of nosocomial TB transmission.
Correspondence: Stephen D. Lawn, Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of
Health Sciences, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa. Tel +27 21 650 6970, Fax +27
21 650 6963, stevelawn@yahoo.co.uk.
Conflicts of interest
The authors have no conflicts of interest to declare
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing
this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it
is published in its final citable form. Please note that during the production process errors may be discovered which could affect the
content, and all legal disclaimers that apply to the journal pertain.
Europe PMC Funders Group
Author Manuscript
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 January 01.
Published in final edited form as:
J Acquir Immune Defic Syndr. 2012 July 1; 60(3): 289–294. doi:10.1097/QAI.0b013e318258c6af.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
A range of new diagnostics for TB is now emerging, employing various different
technologies.8 One area of renewed interest has focused on the potential for TB diagnosis to
be made from analysis of urine samples. Urine is an attractive sample for diagnosis as it is
simple to obtain, even from very ill patients who may not be able to produce sputum. Urine
sampling does not generate hazardous infectious aerosols and urine is relatively clean and
easy to handle in the laboratory. Urine may be cultured,9 tested by polymerase chain
reaction (PCR) for mycobacterial transrenal DNA10 or tested for specific mycobacterial
antigens such as lipoarabinomannan (LAM).11-13
More recently, the Xpert MTB/RIF rapid molecular assay14,15 (hereafter referred to as
‘Xpert’) has been endorsed by the World Health Organization (WHO) as a replacement for
sputum smear microscopy.16 However, there are also reports of Xpert being used to
diagnose TB by testing a range of extrapulmonary samples, including urine.17,18 In this
study, we therefore determined the diagnostic sensitivity of Xpert MTB/RIF when testing
small volumes of urine obtained from HIV-infected patients being screened for TB prior to
starting antiretroviral therapy (ART) in South Africa.
METHODS
The ART service in Gugulethu township, Cape Town, South Africa, and the burden of TB
among these patients have previously been described.2,19 The patients in this study were
enrolled into the parent study12 between 12th March 2010 and 20th April 2011 to assess the
diagnostic accuracy of the urine LAM point-of-care assay (Determine TB-LAM).
Consecutive eligible HIV-infected patients were recruited from among patients newly
referred to the clinic for ART. Study eligibility criteria included age >18 years, being ART-
naive and having no current TB diagnosis. All participants provided written informed
consent and the study was approved by the research ethics committees of the University of
Cape Town, South Africa, and the London School of Hygiene & Tropical Medicine, UK.
Following recruitment at their first visit to the clinic, patients’ demographic details were
recorded and they were clinically characterized. A standardised TB symptom-screening
questionnaire (including the WHO symptom screen for HIV-associated TB20) was
completed and routine baseline investigations and screening tests for TB were done. Two
sputum samples were requested from each patient; a spot specimen was first obtained
followed by a second obtained by induction using nebulised 3% hypertonic saline. Urine
samples were also collected and stored at −20°C within 3 hours. Blood CD4 cell counts and
plasma viral load were measured on all patients via the routine laboratory services. Chest
radiographs were obtained and reported by an experienced reader certified in the use of the
chest radiograph reading and recording system.21,22
Patients were followed up within the routine ART service and patients diagnosed as having
TB were referred to TB clinics within the township for treatment. ART service records of
those with TB were reviewed to ascertain deaths within the first 90 days after enrolment.
Laboratory procedures
Sputum specimens were processed using standardised protocols and quality assurance
procedures by a centralised accredited laboratory as described in detail previously.12,23 In
brief, samples were decontaminated with N-acetyl-L-cysteine and sodium hydroxide and
concentrated by centrifugation. Smears prepared from the sputum pellets underwent
fluorescence microscopy. Equal volumes of the remaining pellet were tested by the Xpert
assay and by liquid culture using Mycobacterial Growth Indicator Tubes (MGIT, Becton
Dickinson, Sparks, Maryland, USA), which were incubated for up to 6 weeks. Cultures
positive for acid-fast bacilli were identified as Mycobacterium tuberculosis complex using
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the MTBDRplus assay (Hain Lifesciences, Nehren, Germany), which also provided
genotypic assessment of susceptibility to rifampicin and isoniazid. Phenotypic drug
susceptibility testing was also done in liquid culture using the modified proportion method.
Frozen urine samples were defrosted and retrospectively analysed for the presence of LAM
using both the Clearview MTB-ELISA (Alere, Waltham, MA, USA) the Determine TB-
LAM point-of-care test strips (Alere, Lot #101102) with strict adherence to the
manufacturer’s instructions.12 Defrosted urine samples (2.0 mL) were also concentrated by
centrifugation, the pellet resuspended in 0.75 mL of phosphate buffer and then tested using
the Xpert assay according to the manufacturer’s instructions.
Definitions and analysis
Patients were defined as having TB if Mycobacterium tuberculosis was cultured from one or
more sputum samples. Patients were then categorized as having urine Xpert-positive or urine
Xpert-negative disease. Clinical, microbiological and radiological characteristics and 90-day
outcomes of patients with Xpert-positive and Xpert–negative TB were compared using the
Wilcoxon rank-sum test, t-test, chi-square and Fisher’s exact tests as appropriate. Logistic
regression analysis was used to identify factors independently associated with urine Xpert-
positive test results. All statistical tests were two-sided at alpha=0.05.
RESULTS
TB diagnoses
Among 602 patients recruited, 535 produced at least 1 sputum sample and a specimen of
urine. Sputum culture results were available from 516 patients and these yielded 85
diagnoses of culture-positive TB. The remainder (n=431) were sputum culture-negative. TB
cases were young adults of whom more than one half were female (Table 1). The median
plasma viral load was high and the median (interquartile range) CD4 cell count was 138
cells/μL (IQR 63-205). A positive WHO TB symptom screen was recorded in 82.1% of TB
patients but only 25.0% reported a cough lasting ≥2 weeks. Disease was sputum smear-
positive in 28.6% of cases and smear-negative in 71.4% (Table 1). Xpert testing of sputum
was positive in 58.3% from the first sample and 70.2% when testing both sputum samples.
Yield of TB diagnoses from testing urine with Xpert MTB/RIF
Of the patients with sputum culture-positive TB and available urine Xpert results (n=84), 16
tested positive, giving a sensitivity of 19.0% (95%CI, 11.3-29.1). The sensitivity was
strongly associated with blood CD4 cell count (Figure 1a). It was higher in those with
counts <50 cells/μL (44.4%; 95%CI, 21.5-69.2) compared to those with counts of 50-150
cells/μL (25.0%; 95%CI, 10.7-44.9) or >150 cells/μL (2.7%; 95%CI, 0.1-14.2).
Xpert testing of both sputum and urine samples produced a small incremental diagnostic
yield over Xpert testing of sputum only. When Xpert testing was done on one sputum
sample, an additional 4 cases of TB were diagnosed by also testing urine samples with Xpert
(sensitivity: 58.3% versus 63.1%). When testing 2 sputum samples, an additional 2 cases of
TB were diagnosed by also testing urine samples with Xpert (70.2% vs 72.6%).
The sensitivity of urine Xpert testing was approximately two-thirds of that observed using
the Determine TB-LAM point-of-care assay for LAM. The overall sensitivity of this assay
for all TB patients was 28.6% (19.2-39.5) and for those with CD4 cell counts of <50 cells/
μL, 50-150 cells/μL and >150 cells/μL, sensitivities were 66.7% (41.0-86.7), 32.1%
(15.9-52.4) and 8.1% (1.7-21.9), respectively (Figure 1b).
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Comparison of urine Xpert-positive and negative cases
We compared the characteristics and microbiological results of patients with urine Xpert-
positive (n=16) and urine Xpert-negative (n=68) disease (Table 1). Those with urine Xpert-
positive disease were younger, tended to have lower body mass indices and haemoglobin
concentrations and higher neutrophil counts. They also had more advanced HIV, with higher
viral loads and a much lower median CD4 cell count compared to patients with urine Xpert-
negative disease.
Multivariate logistic regression analysis was done and this included CD4 cell count, viral
load and those patient characteristics and blood tests results that were found to be
significantly associated with Xpert status in univariate analysis in Table 1. A positive urine
Xpert result was independently associated with just two patient characteristics - younger age
and lower CD4 cell counts. Assigning patients with CD4 cell counts of >150 cells/μL as the
reference group, the adjusted odds of a positive urine Xpert result among patients with CD4
cell counts of either 50-150 cells/μL or <50 cells/μL were 13.6 (95%CI, 1.33-139) and 20.1
(95%CI, 1.72-233), respectively (P=0.010).
Although there were no significant differences in the pulmonary radiographic features of
disease comparing the two groups of patients (Table 1), patients with urine Xpert-positive
TB had evidence of high mycobacterial burden. They had higher frequencies of positive
sputum smear microscopy and positive sputum Xpert results, shorter time to culture
positivity and a higher frequency of detectable LAM in urine (Table 1).
Drug resistance
Four cases of multi-drug resistant TB (MDR-TB) were confirmed by phenotypic and
genotypic assessment of sputum culture isolates. Rifampicin resistance was detected in all of
these cases by Xpert testing of sputum. Xpert detected M. tuberculosis in the urine of only
one of these patients but correctly identified rifampicin resistance. In addition, results of
Xpert done on urine samples also reported rifampicin resistance in two other patients whose
sputum isolates were drug susceptible. These were either false-positive Xpert results or
represented mixed infection with resistant and susceptible strains.
Urine samples from non-TB cases
Of patients (n=431) with negative sputum cultures, we tested urine samples from a sample
of consecutive patients equal in number to the TB cases studied (n=84). The characteristics
of these patients (data not shown) were very similar to those of non-TB patients in the
overall cohort included in the parent study,12 indicating that these were a representative
sample. Urine specimens from these 84 patients were tested using Xpert and all were
negative.
Mortality
Outcomes up to 90 days from screening were assessed. During follow-up, 4/16 (25%) of
urine Xpert-positive patients died compared to 1/68 (1.5%) of urine Xpert-negative patients
(P=0.004). All deaths occurred within the first 30 days.
DISCUSSION
In this study, one fifth of ambulatory HIV-infected patients with advanced
immunodeficiency and sputum culture-positive pulmonary TB had M. tuberculosis that was
detectable when testing small volumes of urine with the Xpert assay. The diagnostic yield
was strongly associated with blood CD4 cell count with almost one half of those with CD4
cell counts <50 cells/μL testing positive whereas the yield at CD4 counts >150 cells/μL was
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very low. There was a small incremental diagnostic yield from Xpert assays when spot urine
samples were tested in addition to sputum samples. This represents an alternative rapid
diagnostic modality in HIV-infected patients with advanced immunodeficiency.
Previous studies have reported that concentration of urine from HIV-infected patients by
centrifugation and subsequent culture has an appreciable diagnostic yield.9,24,25 However,
this entails collection and processing of comparatively large volumes of urine, for example
pooling morning samples over three days.25 Urine culture is infrequently useful as a
diagnostic modality in this clinical population because of the prolonged time to culture
positivity. In this study, however, we tested very small (2.0 ml) samples of urine and still
found an important diagnostic yield that was similar to that obtained by culture of
concentrated large volumes of urine in a study of HIV-infected patients in Thailand.9 The
sensitivity of Xpert in our study might have been even greater had a whole urine sample
been collected and concentrated.
A major advantage of Xpert is rapidity, with results being generated within 2 hours
compared with culture for which the time to positivity often exceeds 3 weeks for
paucibacillary clinical samples.11,23 Rapid diagnosis is particularly important for patients
with high mortality risk. Our analyses demonstrated that similar to sputum testing,26 urine
Xpert testing is most likely to be positive in patients with the most advanced
immunodeficiency and poor prognostic characteristics (low body mass indices and low
haemoglobin concentrations). One quarter of those who retrospectively tested urine Xpert-
positive TB died. Thus, this represents a particularly useful diagnostic modality in patients
with low CD4 cell counts and high risk of death. We assessed ambulatory patients and yet
the assay may have even greater utility among sick patients requiring hospital admission
who may be unable to obtain good quality sputum samples and in whom risk of
disseminated TB is high.5
In contrast to detection in urine of non-organism-associated transrenal DNA fragments, the
Xpert assay detects intact Mycobacterium tuberculosis bacilli. This is because the cartridge-
based processing entails sputum lysis, washing and deposition of whole mycobacteria on a
filter membrane prior to ultrasonic disruption and real-time PCR amplification and
detection.15 Thus, detection of M. tuberculosis in urine using Xpert indicates renal tract
involvement with TB as the bacilli would otherwise be unable to enter the urine. The
sensitivity of urine Xpert was approximately two-thirds that of Determine TB-LAM which,
in contrast to Xpert, detects mycobacterial cell wall LAM antigen rather than the whole
organism. This is consistent with findings from another study from Cape Town investigating
the mechanisms of LAM antigenuria.27 We do not know whether the sensitivity of urine
Xpert might have been similar to that of the LAM assay had much larger volumes of urine
been concentrated by centrifugation prior to testing.
Xpert has been found to have very high sensitivity but sub-optimal specificity for rifampicin
resistance.15 In this study, two patients had rifampicin resistant M. tuberculosis when testing
urine with Xpert, but the strains isolated from sputum were susceptible. It is not possible to
ascertain whether these are false-positives (which are usually stochastic events, related to
poor binding of detection probe B to the amplicon during the assay15) or whether the
patients could have had disease due to two different strains. It was not possible to investigate
this with molecular typing without paired isolates.
It was notable that urine Xpert results were only positive in patients with positive sputum
cultures and were negative in all those who tested sputum culture-negative. Detection of M.
tuberculosis in both urine and sputum samples indicates the presence of disseminated
disease with both pulmonary and renal tract involvement and this also reflects the lack of
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disease anatomic compartmentalization in patients with advanced immunodeficiency.
Assessment of both sputum and urine samples using Xpert provides a means of rapid
assessment for disseminated TB.
Strengths of this study include the recruitment of carefully characterised consecutive
patients in a well documented clinical cohort. We do not know whether the diagnostic yield
might have been greater had larger volumes of urine been tested and the relative sensitivity
of urine Xpert and urine culture was not assessed. Urine testing was done retrospectively
and it is not known whether prospective testing would have accelerated diagnosis or
improved patient outcomes. Further prospective evaluation is needed to determine whether
this provides a useful diagnostic modality during clinical care in both high and low TB
burden settings.
In conclusion, analysis of urine samples using the Xpert assay provides useful diagnostic
yield for TB among patients with advanced HIV-associated immunodeficiency. High rates
of detection among those with low CD4 cell counts provide evidence of frequent disease
dissemination.
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Figure 1.
(a) The sensitivity (%, 95%CI) of the Xpert MTB/RIF assay for tuberculosis (TB) when
testing urine samples obtained from HIV-infected patients (n=84) with sputum culture-
confirmed pulmonary TB. Sensitivity is also shown stratified by CD4 cell count for the 83
patients for whom CD4 cell counts were available. (b) Comparison of the sensitivity of urine
Xpert with that of Determine TB-LAM Ab point-of-care diagnostic assay that diagnoses TB
by detecting mycobacterial lipoarabinomannan (LAM) in urine.
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Table 1
Characteristics and results of radiological and microbiological investigations in patients with sputum culture-
positive tuberculosis (TB), comparing those whose urine samples tested Xpert-positive with those whose
samples tested Xpert-negative.
Total TB cases
(n=84)
Urine Xpert-
positive cases
(n=16)
Urine Xpert-
negative, cases
(n=68)
P-valuea
Patient characteristics
 Age, median (IQR) 33.1 (28.4-40.2) 27.6 (25.0-31.1) 34.1 (28.9-41.4) 0.006
 Female (%) 51 (60.7) 8 (50) 43 (63.2) 0.329
 BMI, median (IQR) 21.2 (19.2-26.0) 19.0 (17.8-24.4) 21.3 (19.8-26.4) 0.072
 History of previous TB? 18 (21.4) 4 (25.0) 14 (20.6) 0.739
Blood Tests b
 Hemoglobin (g/dL) 10.9 (8.8-12.4) 9.0 (7.7-10.9) 11.2 (9.2-12.7) 0.003
 White blood cell count
 ( ×109 cells/ L) 5.6 (4.6-7.7) 5.7 (5-11.2) 5.6 (4.5-7.1) 0.330
 Absolute neutrophil count
 ( ×109 cells/ L) 3.3 (2.4-5.0) 4.8 (2.4-9.1) 3.2 (2.4-4.2) 0.047
 Absolute lymphocyte count
 ( ×109 cells/ L) 1.0 (1.0-2.1) 1.2 (0.6=2.1) 1.6 (1.2-2.1) 0.128
 ALT (iu/L) 21.5 (14-33.5) 26 (17-58) 20 (13.5-32) 0.060
 Platelets (×109 cells/ L) 289 (219-383) 309 (163-418.5) 282 (228.5-377.5) 0.791
CD4 cell count (cells/μL)c
 Median 138 (63-205) 60 (25-113) 161 (72-213) 0.001
 CD4 <50 18 (21.7) 8 (50) 10 (14.9)
0.001 CD4 50-150 28 (33.7) 7 (43.8) 21 (31.3)
 CD4 >150 37 (44.6) 1 (6.3) 36 (53.7)
 Log viral load (copies/ml),
 Median (IQR)b 4.8 (4.4-5.3) 5.2 (4.8-5.6) 4.7 (4.3-5.2) 0.015
WHO stage at enrolment
 1 or 2 47 (56.0) 7 (43.8) 40 (58.8)
0.275
 3 or 4 37 (44.1) 9 (56.3) 28 (41.2)
Symptoms
 Any cough, fever, night
 sweats or weight loss (≥1
 symptom)
69 (82.1) 13 (81.3) 56 (82.4) 1.00
 Current cough ≥ 2 weeks 21 (25.0) 6 (37.5) 15 (22.1) 0.199
Chest radiographs
 Any radiological
 abnormalitya
62/81 (76.5) 14/16 (87.5) 48/65 (73.9) 0.335
 Hilar and mediastinal
 lymphadenopathy 23/81 (28.4) 7 (43.8) 16 (24.6) 0.128
 Cavitation 2 (2.5) 0 2 (3.1) 1
 Parenchymal abnormality 3 (1-5) 2.5 (1-6) 3 (2-4.5) 0.919
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Total TB cases
(n=84)
Urine Xpert-
positive cases
(n=16)
Urine Xpert-
negative, cases
(n=68)
P-valuea
 (median number of zones)
Microbiological investigations
 Smear positive 24 (28.6) 9 (56.3) 15 (22.1) 0.006
 Time to culture positivity
 median IQR (days) 16 (11-21) 11 (8.5-19.5) 16 (12-21) 0.066
 Sputum Xpert positive (first
 result only) 49 (58.3) 12 (75.0) 37 (54.4) 0.133
 Sputum Xpert positive
 (either result positive) 59 (70.2) 14 (87.5) 45 (66.2) 0.131
 Urine LAM ELISA positive 23 (27.4) 12 (75.0) 11 (16.2) <0.001
 Determine-TB LAM
 positive 24 (28.6) 12 (75.0) 12 (17.7) <0.001
ALT = alanine aminotransferase
aComparison of Xpert-positive and Xpert-negative cases.
b
Blood tests show median values (interquartile range [IQR]). All other results show numbers (%) unless otherwise stated.
cCD4 cell counts missing from 1 urine Xpert-negative patient.
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 January 01.
